Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Genitourinary 1

Conditions

Urinary Bladder Neoplasms 8Carcinoma, Transitional Cell 8Breast Neoplasms 7Lung Neoplasms 6Ovarian Neoplasms 5Prostatic Neoplasms 4Pancreatic Neoplasms 4Neoplasms 4Neoplasm Metastasis 4Carcinoma, Renal Cell 4Carcinoma, Non-Small-Cell Lung 4Testicular Neoplasms 3Stomach Neoplasms 3Sarcoma 3Melanoma 3Fallopian Tube Neoplasms 3Esophageal Neoplasms 3Endometrial Neoplasms 3Oropharyngeal Neoplasms 2Neoplasms, Unknown Primary 2Mouth Neoplasms 2Lymphoma, Non-Hodgkin 2Hypopharyngeal Neoplasms 2Head and Neck Neoplasms 2Carcinoma, Ovarian Epithelial 2Uterine Cervical Neoplasms 1Urethral Neoplasms 1Triple Negative Breast Neoplasms 1Thrombocytosis 1Teratoma, Testicular 1

Interventions

olaparib 1liposomal doxorubicin 1durvalumab 1cediranib 1Topotecan 1Taxes 1Specimen Handling 1Paclitaxel 1Magnetic Resonance Spectroscopy 1Immunoglobulin G 1Doxorubicin 1Disulfides 1Contrast Media 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Fallopian Tube Mucinous Adenocarcinoma × Taxes × Genitourinary × Clear all
NCT04739800 2026-05-29

Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents

National Cancer Institute (NCI)

Phase 2 Active not recruiting
120 enrolled 19 charts
GenitourinaryGynecologic

Fallopian Tube Mucinous Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡